Literature DB >> 22718021

Deciphering transcription dysregulation in FSH muscular dystrophy.

Melanie Ehrlich1, Michelle Lacey.   

Abstract

DUX4, a homeobox-containing gene present in a tandem array, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominant autosomal disease. New findings about DUX4 have raised as many fundamental questions about the molecular pathology of this unique disease as they have answered. This review discusses recent studies addressing the question of whether there is extensive FSHD-related transcription dysregulation in adult-derived myoblasts and myotubes, the precursors for muscle repair. Two models for the role of DUX4 in FSHD are presented. One involves transient pathogenic expression of DUX4 in many cells in the muscle lineage before the myoblast stage resulting in a persistent, disease-related transcription profile ('Majority Rules'), which might be enhanced by subsequent oscillatory expression of DUX4. The other model emphasizes the toxic effects of inappropriate expression of DUX4 in only an extremely small percentage of FSHD myoblasts or myotube nuclei ('Minority Rules'). The currently favored Minority Rules model is not supported by recent studies of transcription dysregulation in FSHD myoblasts and myotubes. It also presents other difficulties, for example, explaining the expression of full-length DUX4 transcripts in FSHD fibroblasts. The Majority Rules model is the simpler explanation of findings about FSHD-associated gene expression and the DUX4-encoded homeodomain-type protein.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718021      PMCID: PMC3562129          DOI: 10.1038/jhg.2012.74

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  98 in total

1.  Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Authors:  Sara T Winokur; Yi-Wen Chen; Peter S Masny; Jorge H Martin; Jeffrey T Ehmsen; Stephen J Tapscott; Silvere M van der Maarel; Yukiko Hayashi; Kevin M Flanigan
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

2.  Cdx function is required for maintenance of intestinal identity in the adult.

Authors:  Alexa Hryniuk; Stephanie Grainger; Joanne G A Savory; David Lohnes
Journal:  Dev Biol       Date:  2012-01-21       Impact factor: 3.582

3.  Retention of Pax3 expression in satellite cells of muscle spindles.

Authors:  Lisa J Kirkpatrick; Zipora Yablonka-Reuveni; Benjamin W C Rosser
Journal:  J Histochem Cytochem       Date:  2009-12-21       Impact factor: 2.479

Review 4.  Hox genes and regional patterning of the vertebrate body plan.

Authors:  Moises Mallo; Deneen M Wellik; Jacqueline Deschamps
Journal:  Dev Biol       Date:  2010-05-07       Impact factor: 3.582

5.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

6.  The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes.

Authors:  R Lyle; T J Wright; L N Clark; J E Hewitt
Journal:  Genomics       Date:  1995-08-10       Impact factor: 5.736

7.  Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD.

Authors:  J C de Greef; M Wohlgemuth; O A Chan; K B Hansson; D Smeets; R R Frants; C M Weemaes; G W Padberg; S M van der Maarel
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910

Review 8.  Facioscapulohumeral muscular dystrophy.

Authors:  Rabi Tawil
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

9.  A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene.

Authors:  Andreas Leidenroth; Jane E Hewitt
Journal:  BMC Evol Biol       Date:  2010-11-26       Impact factor: 3.260

10.  DNaseI hypersensitivity at gene-poor, FSH dystrophy-linked 4q35.2.

Authors:  Xueqing Xu; Koji Tsumagari; Janet Sowden; Rabi Tawil; Alan P Boyle; Lingyun Song; Terrence S Furey; Gregory E Crawford; Melanie Ehrlich
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

View more
  4 in total

1.  Early de novo DNA methylation and prolonged demethylation in the muscle lineage.

Authors:  Koji Tsumagari; Carl Baribault; Jolyon Terragni; Katherine E Varley; Jason Gertz; Sirharsa Pradhan; Melody Badoo; Charlene M Crain; Lingyun Song; Gregory E Crawford; Richard M Myers; Michelle Lacey; Melanie Ehrlich
Journal:  Epigenetics       Date:  2013-02-15       Impact factor: 4.528

2.  Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.

Authors:  Céline Vanderplanck; Alexandra Tassin; Eugénie Ansseau; Sébastien Charron; Armelle Wauters; Céline Lancelot; Kelly Vancutsem; Dalila Laoudj-Chenivesse; Alexandra Belayew; Frédérique Coppée
Journal:  Skelet Muscle       Date:  2018-01-12       Impact factor: 4.912

3.  DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?

Authors:  Alexandra Tassin; Dalila Laoudj-Chenivesse; Céline Vanderplanck; Marietta Barro; Sébastien Charron; Eugénie Ansseau; Yi-Wen Chen; Jacques Mercier; Frédérique Coppée; Alexandra Belayew
Journal:  J Cell Mol Med       Date:  2012-12-04       Impact factor: 5.310

4.  Type 1 FSHD with 6-10 Repeated Units: Factors Underlying Severity in Index Cases and Disease Penetrance in Their Relatives Attention.

Authors:  Emmanuelle Salort-Campana; Farzad Fatehi; Sadia Beloribi-Djefaflia; Stéphane Roche; Karine Nguyen; Rafaelle Bernard; Pascal Cintas; Guilhem Solé; Françoise Bouhour; Elisabeth Ollagnon; Sabrina Sacconi; Andoni Echaniz-Laguna; Thierry Kuntzer; Nicolas Levy; Frédérique Magdinier; Shahram Attarian
Journal:  Int J Mol Sci       Date:  2020-03-23       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.